Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pemetrexed disodium
Find trials that include:  Any drugs shown
Results 1-25 of 42 for your search:
Start Over
Nintedanib (BIBF 1120) in Mesothelioma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.93, NCI-2013-01643, 2012-005201-48, NCT01907100
A Study of Atezolizumab (MPDL3280A) Compared With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29431, NCI-2015-01580, 2014-003083-21, NCT02409342
Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-189, NCI-2015-02271, 2015-003694-15, NCT02578680
Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 60107, NCI-2009-01250, CCCWFU-IRB00003457, CDR0000578838, LILLY-CCCWFU-60107, NCT01580449, P30CA012197, NCT00573989
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHI-76, NCI-2015-00127, 9837, NCT02535312
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Pemetrexed Disodium or Observation in Treating Patients with Malignant Pleural Mesothelioma without Progressive Disease after First-Line Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CALGB-30901, NCI-2011-02023, CDR0000667496, NCT01085630
GSK1120212 Rollover Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Afatinib Dimaleate, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-464, NCI-2012-01535, 1200.158, NCT01553942
Maintenance Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Previously Treated Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 092013-070, NCI-2014-02014, NCT02045446
Pemetrexed Disodium with or without Crizotinib in Treating Patients with Stage IV Non-small Cell Lung Cancer That Has Progressed after Treatment with Crizotinib Alone
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1300, NCI-2014-00685, NCT02134912
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MORAb-009-201, NCI-2015-01754, NCT02357147
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-121-01-02-09, NCI-2015-00560, NCT02387216
Pemetrexed Disodium in Treating Patients with Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU # 62115, NCI-2015-00596, NCT02426658
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients with Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: EA5123, NCI-2015-01054, NCT02607423
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients with Recurrent or Metastatic Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-14-10790, NCI-2015-02190, NCT02624700
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AFT-09, NCI-2016-00099, NCT02591615
Start Over